Study S003306

A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07232732
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 120
Start: 2025-10-27
Primary completion: 2026-07-16
Lead sponsor: Eli Lilly and Company
Conditions: Healthy; Obesity; Overweight
Interventions: DRUG:LY3549492
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J3H-MC-GZNJ

Registered primary outcomes

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through end of the Follow-up Period (Week 10)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.